Lipid Metabolism and Endocrine Resistance in Prostate Cancer, and New Opportunities for Therapy
Division of Medical Oncology, University of Colorado School of Medicine, Genitourinary Cancer Program, MS 8117, 12801 E. 17th Ave, Room L18-8119, Aurora, CO 80045, USA
*
Author to whom correspondence should be addressed.
Int. J. Mol. Sci. 2019, 20(11), 2626; https://doi.org/10.3390/ijms20112626
Received: 12 May 2019
/
Revised: 24 May 2019
/
Accepted: 27 May 2019
/
Published: 28 May 2019
(This article belongs to the Special Issue Hormones-Dependent Cancers: New Aspects on
Biochemistry and Molecular Pathology (II))
Prostate cancer (PCa) is the most common cancer in men, and more than 10% of men will be diagnosed with PCa during their lifetime. Patients that are not cured with surgery or radiation are largely treated with endocrine therapies that target androgens or the androgen receptor (AR), a major driver of PCa. In response to androgen deprivation, most PCas progress to castrate resistant PCa, which is treated with anti-androgens like enzalutamide, but tumors still progress and become incurable. Thus, there is a critical need to identify cellular pathways that allow tumors to escape anti-androgen therapies. Epidemiological studies suggest that high-fat diets play important roles in PCa progression. Lipid metabolism rewires the PCa metabolome to support growth and resistance to endocrine therapies, although the exact mechanisms remain obscure. Therapeutic effects have been observed inhibiting several aspects of PCa lipid metabolism: Synthesis, uptake, and oxidation. Since AR remains a driver of PCa in advanced disease, strategies targeting both lipid metabolism and AR are starting to emerge, providing new opportunities to re-sensitize tumors to endocrine therapies with lipid metabolic approaches.
View Full-Text
Keywords:
lipid synthesis; lipid oxidation; AR; prostate cancer; CPT1A; FASN; endocrine resistance; anti-androgens; dietary lipids; combination therapy
▼
Show Figures
Graphical abstract
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited
MDPI and ACS Style
Stoykova, G.E.; Schlaepfer, I.R. Lipid Metabolism and Endocrine Resistance in Prostate Cancer, and New Opportunities for Therapy. Int. J. Mol. Sci. 2019, 20, 2626. https://doi.org/10.3390/ijms20112626
AMA Style
Stoykova GE, Schlaepfer IR. Lipid Metabolism and Endocrine Resistance in Prostate Cancer, and New Opportunities for Therapy. International Journal of Molecular Sciences. 2019; 20(11):2626. https://doi.org/10.3390/ijms20112626
Chicago/Turabian StyleStoykova, Gergana E., and Isabel R. Schlaepfer. 2019. "Lipid Metabolism and Endocrine Resistance in Prostate Cancer, and New Opportunities for Therapy" International Journal of Molecular Sciences 20, no. 11: 2626. https://doi.org/10.3390/ijms20112626
Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.
